A Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors

About this Study

The purpose of this study is to determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is more effective but not significantly more toxic than standard BEP as first-line chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).

Sponsor Protocol ID:AGCT1532
IRB Number:2019-0014
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
11 years old
45 years old
Both Male and Female
Yes
Yes
No

Inclusion Criteria
  • Age ≥ 11 years and ≤ 45 years on the date of randomisation.  
  •  Study treatment both planned and able to start within 14 days of randomisation. 
  • Willing and able to comply with all study requirements, including treatment, timing and nature of required assessments. 
  • Able to provide signed, written informed consent.

Exclusion Criteria

Patients must meet all inclusion and exclusion criteria at the time of registration.


Categories Click category to view its trials.
Cancer
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-815-9390
Email: mgoad@umc.edu
Principal Investigator:Betty H Melton
How to participate in our Clinical Trials